<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346254</url>
  </required_header>
  <id_info>
    <org_study_id>GCPD</org_study_id>
    <nct_id>NCT01346254</nct_id>
  </id_info>
  <brief_title>Glucose Control in Pre-Diabetic Renal Transplant Patients</brief_title>
  <acronym>GCPD</acronym>
  <official_title>Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcus Saemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of New-Onset Diabetes after Transplantation (NODAT) is common and serious
      complication after kidney transplantation. Patients who develop NODAT are at increased risk
      for loss of the transplanted organ and for diseases of the cardiovascular system.

      It is believed that in many patients the development of overt NODAT is preceded by a phase of
      impaired glucose tolerance that is called pre-diabetes.

      This study aims at improving glucose metabolism in patients after kidney transplantation who
      are in a pre-diabetic metabolic state. Patients who exhibit impaired glucose tolerance (IGT)
      after kidney transplantation are randomized to either receive vildagliptin (Galvus),
      pioglitazone(Actos) or placebo for three months.

      The investigators hypothesize that treatment with vildagliptin or pioglitazone leads to
      improved glycemic control compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral glucose tolerance test (OGTT)</measure>
    <time_frame>three months</time_frame>
    <description>Glucose tolerance and insulin resistance three months after study start will be measured by means of a frequent sampling OGTT (75g glucose, determination of glucose, insulin and C-peptide) over 120 mins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glycated hemoglobin</measure>
    <time_frame>3 months</time_frame>
    <description>HbA1c will be measured after three months and compared between the study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>3 months</time_frame>
    <description>Renal function will be assessed by measuring serum creatinin and glomerular filtration rate (GFR)at the beginning of the study and after three months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>3 months</time_frame>
    <description>Liver enzymes (ALAT, ASAT, Gamm-GT) will be measured at the start of the study and after three months treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profiles</measure>
    <time_frame>3 months</time_frame>
    <description>Lipid profiles will be analyzed at the beginning and end of the study including Cholesterol, HDL, LDL and triglycerides.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 patients randomized into this arm will receive placebo medication orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>50mg tablets once daily 20 min before breakfast for 3 months</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>30mg tablets once daily 20 min before breakfast for 3 months</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Life-Style Modification</intervention_name>
    <description>All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Time since renal transplantation &gt; 6 months

          -  Stable graft function

          -  Routine OGTT has been performed, and pre-diabetes has been diagnosed by pathological
             OGTT (2h, 75 g glucose, glucose level between 140 and 200 mg/dl)

          -  Informed consent of the patient

        Exclusion Criteria:

          -  Patients with type 1 or type 2 diabetes

          -  Patients with NODAT (2h glucose level at OGTT &gt;200 mg/dl)

          -  allergy against vildagliptin or pioglitazone

          -  pregnancy

          -  GFR&lt;15ml/min/1.73 with need for dialysis

          -  hepatic impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Säemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien, Universitätskliniken</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Marcus Saemann</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>after</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

